3440 related articles for article (PubMed ID: 34781736)
1. Cross-Neutralization of Emerging SARS-CoV-2 Variants of Concern by Antibodies Targeting Distinct Epitopes on Spike.
Changrob S; Fu Y; Guthmiller JJ; Halfmann PJ; Li L; Stamper CT; Dugan HL; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson SA; Utset HA; Graves HM; Amanat F; Sather DN; Krammer F; Kawaoka Y; Wilson PC
mBio; 2021 Dec; 12(6):e0297521. PubMed ID: 34781736
[TBL] [Abstract][Full Text] [Related]
2. Cross neutralization of emerging SARS-CoV-2 variants of concern by antibodies targeting distinct epitopes on spike.
Wilson P; Changrob S; Fu Y; Guthmiller J; Halfmann P; Li L; Stamper C; Dugan H; Accola M; Rehrauer W; Zheng NY; Huang M; Wang J; Erickson S; Utset H; Graves H; Amanat F; Sather DN; Krammer F; Kawaoka Y
Res Sq; 2021 Jul; ():. PubMed ID: 34312615
[TBL] [Abstract][Full Text] [Related]
3. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment.
Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN
mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691
[TBL] [Abstract][Full Text] [Related]
4. Neutralization potency of monoclonal antibodies recognizing dominant and subdominant epitopes on SARS-CoV-2 Spike is impacted by the B.1.1.7 variant.
Graham C; Seow J; Huettner I; Khan H; Kouphou N; Acors S; Winstone H; Pickering S; Galao RP; Dupont L; Lista MJ; Jimenez-Guardeño JM; Laing AG; Wu Y; Joseph M; Muir L; van Gils MJ; Ng WM; Duyvesteyn HME; Zhao Y; Bowden TA; Shankar-Hari M; Rosa A; Cherepanov P; McCoy LE; Hayday AC; Neil SJD; Malim MH; Doores KJ
Immunity; 2021 Jun; 54(6):1276-1289.e6. PubMed ID: 33836142
[TBL] [Abstract][Full Text] [Related]
5. Escape from neutralizing antibodies by SARS-CoV-2 spike protein variants.
Weisblum Y; Schmidt F; Zhang F; DaSilva J; Poston D; Lorenzi JC; Muecksch F; Rutkowska M; Hoffmann HH; Michailidis E; Gaebler C; Agudelo M; Cho A; Wang Z; Gazumyan A; Cipolla M; Luchsinger L; Hillyer CD; Caskey M; Robbiani DF; Rice CM; Nussenzweig MC; Hatziioannou T; Bieniasz PD
Elife; 2020 Oct; 9():. PubMed ID: 33112236
[TBL] [Abstract][Full Text] [Related]
6. Isolation and Characterization of Mouse Monoclonal Antibodies That Neutralize SARS-CoV-2 and Its Variants of Concern Alpha, Beta, Gamma and Delta by Binding Conformational Epitopes of Glycosylated RBD With High Potency.
Mariotti S; Capocefalo A; Chiantore MV; Iacobino A; Teloni R; De Angelis ML; Gallinaro A; Pirillo MF; Borghi M; Canitano A; Michelini Z; Baggieri M; Marchi A; Bucci P; McKay PF; Acchioni C; Sandini S; Sgarbanti M; Tosini F; Di Virgilio A; Venturi G; Marino F; Esposito V; Di Bonito P; Magurano F; Cara A; Negri D; Nisini R
Front Immunol; 2021; 12():750386. PubMed ID: 34764961
[TBL] [Abstract][Full Text] [Related]
7. Shared N417-Dependent Epitope on the SARS-CoV-2 Omicron, Beta, and Delta Plus Variants.
Moyo-Gwete T; Madzivhandila M; Mkhize NN; Kgagudi P; Ayres F; Lambson BE; Manamela NP; Richardson SI; Makhado Z; van der Mescht MA; de Beer Z; de Villiers TR; Burgers WA; Ntusi NAB; Rossouw T; Ueckermann V; Boswell MT; Moore PL
J Virol; 2022 Aug; 96(15):e0055822. PubMed ID: 35867572
[TBL] [Abstract][Full Text] [Related]
8. A Bispecific Antibody Targeting RBD and S2 Potently Neutralizes SARS-CoV-2 Omicron and Other Variants of Concern.
Yuan M; Chen X; Zhu Y; Dong X; Liu Y; Qian Z; Ye L; Liu P
J Virol; 2022 Aug; 96(16):e0077522. PubMed ID: 35916510
[TBL] [Abstract][Full Text] [Related]
9. Limited Variation between SARS-CoV-2-Infected Individuals in Domain Specificity and Relative Potency of the Antibody Response against the Spike Glycoprotein.
Van Ert HA; Bohan DW; Rogers K; Fili M; Rojas Chávez RA; Qing E; Han C; Dempewolf S; Hu G; Schwery N; Sevcik K; Ruggio N; Boyt D; Pentella MA; Gallagher T; Jackson JB; Merrill AE; Knudson CM; Brown GD; Maury W; Haim H
Microbiol Spectr; 2022 Feb; 10(1):e0267621. PubMed ID: 35080430
[TBL] [Abstract][Full Text] [Related]
10. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants.
Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK
mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456
[TBL] [Abstract][Full Text] [Related]
11. Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.
Yang Y; Zang J; Xu S; Zhang X; Yuan S; Wang H; Lavillette D; Zhang C; Huang Z
Viruses; 2021 Jul; 13(8):. PubMed ID: 34452287
[TBL] [Abstract][Full Text] [Related]
12. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV.
Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X
MAbs; 2021; 13(1):1953683. PubMed ID: 34313527
[TBL] [Abstract][Full Text] [Related]
13. XAV-19, a Swine Glyco-Humanized Polyclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Domain, Targets Multiple Epitopes and Broadly Neutralizes Variants.
Vanhove B; Marot S; So RT; Gaborit B; Evanno G; Malet I; Lafrogne G; Mevel E; Ciron C; Royer PJ; Lheriteau E; Raffi F; Bruzzone R; Mok CKP; Duvaux O; Marcelin AG; Calvez V
Front Immunol; 2021; 12():761250. PubMed ID: 34868003
[TBL] [Abstract][Full Text] [Related]
14. Characterization of a Broadly Neutralizing Monoclonal Antibody against SARS-CoV-2 Variants.
Zakir TS; Meng T; Carmen LCP; Chu JJH; Lin RTP; Prabakaran M
Viruses; 2022 Jan; 14(2):. PubMed ID: 35215823
[TBL] [Abstract][Full Text] [Related]
15. Sequential Analysis of Binding and Neutralizing Antibody in COVID-19 Convalescent Patients at 14 Months After SARS-CoV-2 Infection.
Rosati M; Terpos E; Ntanasis-Stathopoulos I; Agarwal M; Bear J; Burns R; Hu X; Korompoki E; Donohue D; Venzon DJ; Dimopoulos MA; Pavlakis GN; Felber BK
Front Immunol; 2021; 12():793953. PubMed ID: 34899762
[TBL] [Abstract][Full Text] [Related]
16. Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.
Planas D; Veyer D; Baidaliuk A; Staropoli I; Guivel-Benhassine F; Rajah MM; Planchais C; Porrot F; Robillard N; Puech J; Prot M; Gallais F; Gantner P; Velay A; Le Guen J; Kassis-Chikhani N; Edriss D; Belec L; Seve A; Courtellemont L; Péré H; Hocqueloux L; Fafi-Kremer S; Prazuck T; Mouquet H; Bruel T; Simon-Lorière E; Rey FA; Schwartz O
Nature; 2021 Aug; 596(7871):276-280. PubMed ID: 34237773
[TBL] [Abstract][Full Text] [Related]
17. Comprehensive characterization of the antibody responses to SARS-CoV-2 Spike protein finds additional vaccine-induced epitopes beyond those for mild infection.
Garrett ME; Galloway JG; Wolf C; Logue JK; Franko N; Chu HY; Matsen FA; Overbaugh JM
Elife; 2022 Jan; 11():. PubMed ID: 35072628
[TBL] [Abstract][Full Text] [Related]
18. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection.
Cao Y; Yisimayi A; Jian F; Song W; Xiao T; Wang L; Du S; Wang J; Li Q; Chen X; Yu Y; Wang P; Zhang Z; Liu P; An R; Hao X; Wang Y; Wang J; Feng R; Sun H; Zhao L; Zhang W; Zhao D; Zheng J; Yu L; Li C; Zhang N; Wang R; Niu X; Yang S; Song X; Chai Y; Hu Y; Shi Y; Zheng L; Li Z; Gu Q; Shao F; Huang W; Jin R; Shen Z; Wang Y; Wang X; Xiao J; Xie XS
Nature; 2022 Aug; 608(7923):593-602. PubMed ID: 35714668
[TBL] [Abstract][Full Text] [Related]
19. Low-dose in vivo protection and neutralization across SARS-CoV-2 variants by monoclonal antibody combinations.
Dussupt V; Sankhala RS; Mendez-Rivera L; Townsley SM; Schmidt F; Wieczorek L; Lal KG; Donofrio GC; Tran U; Jackson ND; Zaky WI; Zemil M; Tritsch SR; Chen WH; Martinez EJ; Ahmed A; Choe M; Chang WC; Hajduczki A; Jian N; Peterson CE; Rees PA; Rutkowska M; Slike BM; Selverian CN; Swafford I; Teng IT; Thomas PV; Zhou T; Smith CJ; Currier JR; Kwong PD; Rolland M; Davidson E; Doranz BJ; Mores CN; Hatziioannou T; Reiley WW; Bieniasz PD; Paquin-Proulx D; Gromowski GD; Polonis VR; Michael NL; Modjarrad K; Joyce MG; Krebs SJ
Nat Immunol; 2021 Dec; 22(12):1503-1514. PubMed ID: 34716452
[TBL] [Abstract][Full Text] [Related]
20. Broadly neutralizing antibodies overcome SARS-CoV-2 Omicron antigenic shift.
Cameroni E; Bowen JE; Rosen LE; Saliba C; Zepeda SK; Culap K; Pinto D; VanBlargan LA; De Marco A; di Iulio J; Zatta F; Kaiser H; Noack J; Farhat N; Czudnochowski N; Havenar-Daughton C; Sprouse KR; Dillen JR; Powell AE; Chen A; Maher C; Yin L; Sun D; Soriaga L; Bassi J; Silacci-Fregni C; Gustafsson C; Franko NM; Logue J; Iqbal NT; Mazzitelli I; Geffner J; Grifantini R; Chu H; Gori A; Riva A; Giannini O; Ceschi A; Ferrari P; Cippà PE; Franzetti-Pellanda A; Garzoni C; Halfmann PJ; Kawaoka Y; Hebner C; Purcell LA; Piccoli L; Pizzuto MS; Walls AC; Diamond MS; Telenti A; Virgin HW; Lanzavecchia A; Snell G; Veesler D; Corti D
Nature; 2022 Feb; 602(7898):664-670. PubMed ID: 35016195
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]